ASML vs PFE: Which Is the Better Buy?

Side-by-side comparison of ASML Holding N.V. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-15.
ASML Holding N.V. · Technology
$1,775.64
+45.0% upside to fair value
Grade B High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
ASML has more upside to fair value (+45.0%). PFE trades at a lower forward P/E (19.2x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric ASML PFE
Current Price $1,775.64 $25.22
Fair Value Estimate $2,574.68 $25.92
Upside to Fair Value +45.0% +2.8%
Market Cap $684.4B $143.7B
Forward P/E 62.1x 19.2x
EV / EBITDA 47.1x 12.3x
Price / Sales 18.4x 2.3x
Price / FCF 69.1x 15.2x
Revenue Growth YoY +13.2% +5.4%
Gross Margin 52.6% 69.3%
Operating Margin 34.8% 23.4%
Return on Equity 52.0% 8.4%
Dividend Yield 0% 0%
FCF Yield 1.45% 6.6%
Analyst Consensus Strong Buy Hold
Investment Thesis
ASML — ASML Holding N.V.
ASML Holding N.V. is a leading semiconductor equipment manufacturer specializing in photolithography systems critical for chip production. The company exhibits high business quality with a durable competitive moat supported by advanced technology and strong market position, reflected in a 52% return on equity and robust margins including a 52.6% gross margin and 29.7% net margin. Despite strong r…
PFE — Pfizer Inc.
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
Metric ASML PFE
Zone Low $1,931.01 $19.44
Zone High $2,188.48 $22.03
In Buy Zone? Yes No
← ASML Research    PFE Research →    All Research